Independent, evidence-based peptide science intelligence. Our editorial team combines expertise in peptide chemistry, molecular pharmacology, and biotech industry analysis.
GHK-Cu is the most studied peptide in skincare, with over 170 published papers exploring how this copper-binding tripeptide repairs aging skin at the cellular level.
TearSolutions' Lacripep, a synthetic peptide derived from human tear protein, has won both Orphan Drug and Fast Track designations from the FDA for neurotrophic keratitis. Phase 2 dosing has begun.
Retatrutide is not FDA-approved for human use. Yet the experimental weight loss peptide is everywhere — TikTok, Instagram, online marketplaces. Here is what the black market craze reveals about the FDA's peptide blind spot.
The FDA will convene an advisory panel July 23–24 to evaluate whether certain peptides should become accessible through licensed compounding pharmacies. The decision could reshape the US peptide market and set a regulatory precedent.
TearSolutions' synthetic peptide Lacripep secured FDA Orphan Drug and Fast Track designations for neurotrophic keratitis, a rare degenerative corneal disease. A Phase 2 trial in 54 patients is now underway.
Parabilis files for Nasdaq IPO after raising $305M privately and securing a Regeneron deal — a milestone for helical peptides that can reach intracellular targets.
Cenna Biosciences wins FDA clearance for a first-in-class peptide that stops amyloid production rather than clearing plaques — a fundamentally different approach to Alzheimer's disease.
GLP-1 prescriptions have more than quadrupled since 2021 and now reach nearly 9,000 per 100,000 U.S. adults. But a 333,000-patient VA study finds that stopping these drugs can erase cardiovascular benefits within months, raising urgent questions about the chronic therapy model.
CordenPharma is acquiring AmbioPharm in a deal that adds peptide API production sites in the US and China, responding to surging GLP-1 manufacturing demand that is reshaping the global CDMO landscape.
Australian peptide biotech Gelteq is entering its first human clinical trial while expanding into veterinary studies, backed by a fresh $3.5 million financing round that signals growing investor appetite for early-stage peptide platforms.
Matrixyl sends a fake distress signal to fibroblasts using a five-amino-acid collagen fragment called KTTKS. Here is the full molecular mechanism, clinical data, and what formulators get wrong about concentration and delivery.
Clean skincare brand Mad Hippie launches the Wrinkle Relaxing Eye Treatment ($34.99) — five peptide complexes including Syn-Ake, Argireline Amplified and Matrixyl Synthe'6 in a retinol- and Botox-free eye cream.
